Supporting the challenges in clinical development of autoimmune diseases
Epidemiological data shows a steady rise in autoimmune disease over the last few decades. There are now more than 80 known types, including Crohn’s disease, psoriasis, and rheumatoid arthritis.
Scientific understanding of inflammatory diseases is progressing. However, unmet needs for sustainable, effective therapies persist. Clinical trial design and patient recruitment is more complex than ever. We have the knowledge to help you overcome the strong competition at site level.
Therapeutically aligned clinical professionals
90+Project Directors, Project Managers and Clinical Trial Managers
200+Clinical studies in inflammatory indications
60,000Patients at 10,000+ global sites involved over 5 years
Global trial experience
We have the insight and experience to deliver an effective operational strategy you're your clinical study. Our work with diverse populations, therapies, and investigational sites informs our planning and executing of high performance in studies.
The following indications are areas where we have specific expertise and a reputation for delivering patient enrollment targets.
Inflammatory bowel diseases
Key indications for inflammatory bowel diseases are: Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease, and eosinophilic esophagitis. Over the past 7 years, we have conducted 46 studies in IBD, involving 4,500 patients at nearly 4,000 sites worldwide.
Dermatology and systemic lupus erythematosus (SLE)
Key indications for dermatology and SLE are: psoriasis, psoriasis arthritis, atopic dermatitis, and SLE. Over the past 5 years, we have conducted 45 clinical trials, enrolling over 12,000 patients from over 1,700 sites.
Key indications for rheumatology are: rheumatoid arthritis, arthritis, and ankylosing spondylitis. Over the past 5 years, we have conducted 38 clinical trials, enrolling over 16,000 patients from over 2,300 sites.
Key indications for respiratory are: asthma, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis, allergic rhinitis and conjunctivitis. Over the past 5 years, we have conducted 36 clinical trials, enrolling over 7,500 patients from over 900 sites.
Our applied innovation combines technology with best practice processes to bring you optimal integrated solutions.
FIRECREST, our clinical site management and e-learning platform, centralises and streamlines communications across the study. This enables transparency in communication and training to our sites and project teams.
ICONIK, our technology platform to analyse the operational and clinical data collected during clinical development. This supports better decision making and the successful implementation of clinical trial strategies, leading to significant efficiencies.